History
MOD3 Pharma has grown to become a leading developer of early phase clinical drug products for OINDP therapies. We changed our name in 2025 to MOD3 Pharma to align with our focus of providing everything our clients need to complete Module 3 of their IND or IMPD and speed their drugs to the clinic.
Originally founded in 2013 as Enteris BioPharma, Inc. from the assets and experienced scientists of Unigene Laboratories. Many of the new employees had decades of experience in manufacturing, analytical testing and regulatory compliance for recombinant drug substances, oral and nasal spray drug products.
